PDCD1 and metastatic neoplasm: To assess the efficacy of CCR2 antagonist and anti-PD-1 combination treatment in models beyond bladder cancer as well as in metastatic disease, we examined the efficacy of this combination in the treatment of B16F10 melanoma pulmonary metastases.